Skip to main content

Pharmaceutical News and Articles

Comprehensive and up-to-date drug news for both consumers and healthcare professionals.

Statin Use Low for Primary Prevention of Atherosclerotic CVD

WEDNESDAY, March 22, 2023 -- Statin use is low for primary prevention of atherosclerotic cardiovascular disease (ASCVD), with the lowest use seen among Black...

Adverse Maternal Outcomes Up With Motor Vehicle Crashes in Pregnancy

WEDNESDAY, March 22, 2023 -- The risk for adverse maternal outcomes is increased for women involved in motor vehicle crashes (MVCs) during pregnancy, according...

Child, Caregiver Mortality Up in Low-Opportunity Neighborhoods

WEDNESDAY, March 22, 2023 -- Children living in neighborhoods with low opportunities for health have an increased risk for child and caregiver mortality...

Children With Autism Less Likely to Receive Vision Screening

WEDNESDAY, March 22, 2023 -- Children with autism spectrum disorder (ASD) are less likely to receive vision screening at well-child visits at ages 3 and 5...

Death Count Climbs in Outbreak Linked to Recalled Eye Drops

WEDNESDAY, March 22, 2023 -- A drug-resistant bacteria linked to recalled eye drops has now killed three people. The U.S. Centers for Disease Control and...

FDA Approves Zynyz (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)

WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 22, 2023-- Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz...

When Kids Lose a Parent, New Therapy Might Prevent Long-Term Mental Harm

WEDNESDAY, March 22, 2023 -- The death of a parent is heartbreaking for a child or teenager, and those who experience it are known to be at an increased risk...

Dealing With Caregiver Stress & Burnout: A Guide

WEDNESDAY, March 22, 2023 -- If you’ve been suffering from caregiver stress, you've got plenty of company. It affects about 36% of the 53 million unpaid...

'Muted' Immune Response May Explain Why COVID Is Tougher for Obese People

WEDNESDAY, March 22, 2023 -- Obesity is a well-known risk factor for severe COVID-19, and researchers think they’ve uncovered a possible reason...

New Technique 80% Effective in Selecting a Baby's Gender

WEDNESDAY, March 22, 2023 -- It's a controversial notion, but couples undergoing fertility treatments may soon be able to select the sex of their baby &mdash...

Florida Bill Would Ban Elementary School Kids From Learning About Menstruation

WEDNESDAY, March 22, 2023 -- A proposed bill in Florida would prevent children from learning about menstruation in elementary school, even though some girls...

Novartis Tafinlar + Mekinist Approved by FDA for Pediatric Patients with BRAF V600E Low-Grade Glioma

New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar +...

FDA Approves Expanded Indication for Telix’s Illuccix to Include Patient Selection for PSMA-Directed Radioligand Therapy

Indianapolis, IN (United States) | 16 March 2023 -- Telix Pharmaceuticals today announces that the United States Food and Drug Administration (FDA) has...

FDA Approves Daybue (trofinetide) for the Treatment of Rett Syndrome

SAN DIEGO–(BUSINESS WIRE)–Mar. 10, 2023– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug...

FDA Approves Zavzpret (zavegepant) Nasal Spray for the Acute Treatment of Migraine

NEW YORK--(BUSINESS WIRE) March 10, 2023 -- Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved Zavzpret...

Ionis Announces FDA Acceptance of New Drug Application for Eplontersen for the Treatment of Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)

35-week data included in the filing demonstrated a statistically significant and clinically meaningful change from baseline for co-primary and secondary...

Avadel Pharmaceuticals Requests Final FDA Approval for Lumryz (sodium oxybate) Extended-Release Oral Suspension

DUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to...

FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma

LEXINGTON, Mass.--(BUSINESS WIRE) March 2, 2023 --Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug...

Cytokinetics Receives Complete Response Letter From FDA for New Drug Application for Omecamtiv Mecarbil

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug...

Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum

WEST CHESTER, PA – February 27, 2023 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology...

Jacobio announces clinical collaboration to evaluate CD73 monoclonal antibody JAB-BX102 in combination with KEYTRUDA for patients with cancer

BEIJING, SHANGHAI and BOSTON, March 22, 2023. Jacobio Pharma (1167.HK) announced it has entered into a clinical collaboration with Merck & Co., Inc...

Diamond Therapeutics Announces FDA-authorized Clinical Trial of Low-Dose Psilocybin in Collaboration with University of Alabama at Birmingham

TORONTO, March 21, 2023. Diamond Therapeutics Inc. ("Diamond"), a drug development company focused on low-dose psychedelic-derived therapies for use in the...

New Yale study evaluates PAXLOVID's use in Long COVID recovery

NEW HAVEN, Conn., March 21, 2023. Yale School of Medicine announces the initiation of a novel, randomized trial that will test whether receiving...

First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia

CAPE CANAVERAL, Fla., March 20, 2023. Vaxxinity, Inc., a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced...

Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity in Distinct Patient Populations with Metastatic Lung and Breast Cancer in Updated Results of Two Early Trials

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE) March 20, 2023 --New data from Daiichi Sankyo’s (TSE: 4568) patritumab deruxtecan (HER3-DXd) from two...

Browse by news type

Drugs.com Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.